ArticleCost effectiveness and resource allocation : C/E2024

Economic evaluation of NALIRIFOX vs. nab-paclitaxel and gemcitabine regimens for first-line treatment of metastatic pancreatic ductal adenocarcinoma from U.S. perspective.

Hanqiao Shao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.